Gilead Sciences Inc

NAS:GILDHealthcareCBOE:SPESGNASDAQ:NBI

$153.07−2.00%At closeAt close · Tue 20 Oct · ≈ AED 562.15 · Market cap $189.8B · Next earnings Thu 29 Oct · Extended $153.13 +0.04%

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	81.5%	75.8%	79.3%	76.0%	78.3%	78.8%	—	—
Operating margin	16.5%	36.3%	26.9%	28.0%	5.8%	39.7%	39.7%	+0.0 pts
Net margin	0.5%	22.8%	16.8%	20.9%	1.7%	28.9%	28.9%	+0.0 pts
EBITDA margin	16.7%	41.5%	32.4%	38.7%	15.4%	46.1%	—	—
Return on equity	0.7%	29.5%	21.6%	24.8%	2.5%	37.5%	37.6%	+0.1 pts
Return on assets	0.2%	9.2%	7.3%	9.1%	0.8%	14.4%	14.4%	+0.0 pts
Return on capital employed	7.1%	17.6%	14.1%	15.0%	3.5%	24.8%	—	—
Debt / equity	1.7×	1.3×	1.2×	1.1×	1.4×	1.1×	1.1×	+0.4%
Debt / assets	45.9%	39.3%	39.9%	40.2%	45.3%	41.7%	—	—
Interest coverage	4.1×	9.9×	7.8×	8.1×	1.7×	11.4×	—	—
Current ratio	1.4×	1.3×	1.3×	1.4×	1.6×	1.7×	1.7×	+0.0%
Quick ratio	1.3×	1.1×	1.2×	1.3×	1.5×	1.3×	—	—
Cash ratio	0.5×	0.5×	0.5×	0.5×	0.8×	0.6×	0.6×	+0.0%
Asset turnover	0.4×	0.4×	0.4×	0.4×	0.5×	0.5×	—	—
Inventory turnover	2.7×	4.1×	3.8×	3.6×	3.7×	1.4×	—	—
Receivables turnover	5.0×	6.1×	5.7×	5.8×	6.5×	6.0×	—	—
Dividend payout	2,804.1%	57.9%	80.8%	67.2%	816.3%	47.0%	—	—

Margins, returns, leverage and liquidityUpdated 31 Dec 2025 ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.